Compare Northrop Grumman Corporation (NOC) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Philip Morris International Inc. — how do they compare? Northrop Grumman Corporation trades at $482.33 (market cap $68.83B), while Philip Morris International Inc. trades at $200.2 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 4.5× Northrop Grumman Corporation's market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and Philip Morris International Inc. for 85 Days on average.
| NOC | PM | |
|---|---|---|
Market Cap | $68.83B | $312.50B |
Volume | 1,081,989 | 5,517,172 |
Sector | Industrials | Consumer Staples |
52-Week High | $768.02 | $200.50 |
52-Week Low | $473.46 | $144.33 |
Typical Hold Time | 81 Days | 85 Days |
Enterprise Value | $82.81B | $355.62B |
Dividend Yield | 2.04% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $479.00, up 1.17% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations, supported by a robust $104.7 billion backlog and expanding defense budgets. Recent news highlights both competitive pressures from Boeing's $20B fighter contract win and positive developments in F-35 radar demand.
The investment outlook remains positive with analyst consensus at $600.62 (25% upside) and 54% buy ratings, though technical indicators suggest near-term pressure. Key risks include contract competition and execution challenges on major programs like the B-21 bomber, while strong cash flow generation and dividend growth provide shareholder support.
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
